Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Calcified Tissue International
Published in: Calcified Tissue International 1/2016

01-01-2016 | Original Research

Impact of Growth Hormone on Adult Bone Quality in Turner Syndrome: A HR-pQCT Study

Authors: Munier A. Nour, Lauren A. Burt, Rebecca J. Perry, David K. Stephure, David A. Hanley, Steven K. Boyd

Published in: Calcified Tissue International | Issue 1/2016

Login to get access

Abstract

Women with Turner syndrome (TS) are known to be at risk of osteoporosis. While childhood growth hormone (GH) treatment is common in TS, the impact of this therapy on bone health has been poorly understood. The objective of this study was to determine the influence of childhood GH treatment on adult bone quality in women with TS. 28 women aged 17–45 with confirmed TS (12 GH-treated) agreed to participate in this cross-sectional study. Dual X-ray absorptiometry (DXA) of lumbar spine, hip, and radius and high-resolution peripheral quantitative computed tomography (HR-pQCT) scans of the radius and tibia were used to determine standard morphological and micro-architectural parameters of bone health. Finite element (FE) analysis and polar moment of inertia (pMOI) were used to estimate bone strength. GH-treated subjects were +7.4 cm taller (95 % CI 2.5–12.3 cm, p = 0.005). DXA-determined areal BMD of hip, spine, and radius was similar between treatment groups. Both tibial and radial total bone areas were greater among GH-treated subjects (+20.4 and +21.2 % respectively, p < 0.05), while other micro-architectural results were not different between groups. pMOI was significantly greater among GH-treated subjects (radius +35.0 %, tibia +34.0 %, p < 0.05). Childhood GH treatment compared to no treatment in TS was associated with an increased height, larger bones, and greater pMOI, while no significant difference in DXA-derived BMD, HR-pQCT micro-architectural parameters, or FE-estimated bone strength was detected. The higher pMOI and greater bone size may confer benefit for fracture reduction in these GH-treated patients.
Literature
1.
Bondy CA (2007) Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 92(1):10–25CrossRefPubMed
2.
Gravholt CH, Juul S, Naeraa RW, Hansen J (1998) Morbidity in Turner syndrome. J Clin Epidemiol 51(2):147–158CrossRefPubMed
3.
Gravholt CH, Vestergaard P, Hermann AP, Mosekilde L, Brixen K, Christiansen JS (2003) Increased fracture rates in Turner’s syndrome: a nationwide questionnaire survey. Clin Endocrinol (Oxf) 59(1):89–96CrossRef
4.
Nour MA, Perry RJ (2014) Current concepts surrounding bone health and osteoporosis in Turner syndrome. Expert Rev Endocrinol Metab 9(5):515–524CrossRef
5.
Cheung AM, Adachi JD, Hanley DA, Kendler DL, Davison KS, Josse R, Brown JP, Ste-Marie L-G, Kremer R, Erlandson MC (2013) High-resolution peripheral quantitative computed tomography for the assessment of bone strength and structure: a review by the Canadian Bone Strength Working Group. Curr Osteoporos Rep 11(2):136–146CrossRefPubMedPubMedCentral
6.
MacNeil JA, Boyd SK (2008) Bone strength at the distal radius can be estimated from high-resolution peripheral quantitative computed tomography and the finite element method. Bone 42(6):1203–1213CrossRefPubMed
7.
Hansen S, Brixen K, Gravholt CH (2012) Compromised trabecular microarchitecture and lower finite element estimates of radius and tibia bone strength in adults with turner syndrome: a cross-sectional study using high-resolution-pQCT. J Bone Miner Res 27(8):1794–1803CrossRefPubMed
8.
Ari M, Bakalov VK, Hill S, Bondy CA (2006) The effects of growth hormone treatment on bone mineral density and body composition in girls with turner syndrome. J Clin Endocrinol Metab 91(11):4302–4305CrossRefPubMed
9.
Aycan Z, Cetinkaya E, Darendeliler F, Vidinlisan S, Bas F, Bideci A, Demirel F, Darcan S, Buyukgebiz A, Yildiz M (2008) The effect of growth hormone treatment on bone mineral density in prepubertal girls with Turner syndrome: a multicentre prospective clinical trial. Clin Endocrinol (Oxf) 68(5):769–772CrossRef
10.
Bakalov VK, Van PL, Baron J, Reynolds JC, Bondy CA (2004) Growth hormone therapy and bone mineral density in Turner syndrome. J Clin Endocrinol Metab 89(10):4886–4889CrossRefPubMed
11.
Bertelloni S, Cinquanta L, Baroncelli GI, Simi P, Rossi S, Saggese G (2000) Volumetric bone mineral density in young women with Turner’s syndrome treated with estrogens or estrogens plus growth hormone. Horm Res 53(2):72–76CrossRefPubMed
12.
Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, van Teunenbroek A, van Leeuwen WJ, Asarfi A, van Rijn RR, Drop SL (2001) Bone mineral density assessed by phalangeal radiographic absorptiometry before and during long-term growth hormone treatment in girls with Turner’s syndrome participating in a randomized dose-response study. Pediatr Res 50(3):417–422CrossRefPubMed
13.
Suganuma N, Furuhashi M, Hirooka T, Moriwaki T, Hasegawa Y, Mori O, Ogawa M (2003) Bone mineral density in adult patients with Turner’s syndrome: analyses of the effectiveness of GH and ovarian steroid hormone replacement therapies. Endocr J 50(3):263–269CrossRefPubMed
14.
Pitukcheewanont P, Numbenjapon N, Safani D, Rossmiller S, Gilsanz V, Costin G (2011) Bone size and density measurements in prepubertal children with Turner syndrome prior to growth hormone therapy. Osteoporos Int 22(6):1709–1715CrossRefPubMed
15.
Bakalov VK, Chen ML, Baron J, Hanton LB, Reynolds JC, Stratakis CA, Axelrod LE, Bondy CA (2003) Bone mineral density and fractures in Turner syndrome. Am J Med 115(4):259–264CrossRefPubMed
16.
Bakalov VK, Axelrod L, Baron J, Hanton L, Nelson LM, Reynolds JC, Hill S, Troendle J, Bondy CA (2003) Selective reduction in cortical bone mineral density in Turner syndrome independent of ovarian hormone deficiency. J Clin Endocrinol Metab 88(12):5717–5722CrossRefPubMed
17.
Holroyd C, Davies J, Taylor P, Jameson K, Rivett C, Cooper C, Dennison E (2010) Reduced cortical bone density with normal trabecular bone density in girls with Turner syndrome. Osteoporos Int 21(12):2093–2099CrossRefPubMed
18.
Soucek O, Lebl J, Snajderova M, Kolouskova S, Rocek M, Hlavka Z, Cinek O, Rittweger J, Sumnik Z (2011) Bone geometry and volumetric bone mineral density in girls with Turner syndrome of different pubertal stages. Clin Endocrinol (Oxf) 74(4):445–452CrossRef
19.
Faul F, Erdfelder E, Buchner A, Lang A-G (2009) Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 41:1149–1160CrossRefPubMed
20.
Berger C, Goltzman D, Langsetmo L, Joseph L, Jackson S, Kreiger N, Tenenhouse A, Davison KS, Josse RG, Prior JC (2010) Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res 25(9):1948–1957CrossRefPubMed
21.
Macdonald HM, Nishiyama KK, Kang J, Hanley DA, Boyd SK (2011) Age-related patterns of trabecular and cortical bone loss differ between sexes and skeletal sites: a population-based HR-pQCT study. J Bone Miner Res 26(1):50–62CrossRefPubMed
22.
Burt LA, Macdonald HM, Hanley DA, Boyd SK (2013) Establishment of T-scores for HR-pQCT using a normative Canadian population. J Clin Densitom 16(3):264–265CrossRef
23.
Burt LA, Macdonald HM, Hanley DA, Boyd SK (2014) Bone microarchitecture and strength of the radius and tibia in a reference population of young adults: an HR-pQCT study. Arch Osteoporos 9(1):183CrossRefPubMed
24.
Katzman DK, Bachrach LK, Carter DR, Marcus R (1991) Clinical and anthropometric correlates of bone mineral acquisition in healthy adolescent girls. J Clin Endocrinol Metab 73(6):1332–1339CrossRefPubMed
25.
Liu D, Burrows M, Egeli D, McKay H (2010) Site specificity of bone architecture between the distal radius and distal tibia in children and adolescents: an HR-pQCT study. Calcif Tissue Int 87(4):314–323CrossRefPubMed
26.
Laib A, Häuselmann HJ, Rüegsegger P (1998) In vivo high resolution 3D-QCT of the human forearm. Technol Health Care 6(5–6):329–337PubMed
27.
Buie HR, Campbell GM, Klinck RJ, MacNeil JA, Boyd SK (2007) Automatic segmentation of cortical and trabecular compartments based on a dual threshold technique for in vivo micro-CT bone analysis. Bone 41(4):505–515CrossRefPubMed
28.
Burghardt AJ, Buie HR, Laib A, Majumdar S, Boyd SK (2010) Reproducibility of direct quantitative measures of cortical bone microarchitecture of the distal radius and tibia by HR-pQCT. Bone 47(3):519–528CrossRefPubMedPubMedCentral
29.
Rubin CT, Lanyon LE (1982) Limb mechanics as a function of speed and gait: a study of functional strains in the radius and tibia of horse and dog. J Exp Biol 101(1):187–211PubMed
30.
Shore RM, Chesney RW, Mazess RB, Rose PG, Bargman GJ (1982) Skeletal demineralization in Turner’s syndrome. Calcif Tissue Int 34(1):519–522CrossRefPubMed
31.
Bechtold S, Rauch F, Noelle V, Donhauser S, Neu C, Schoenau E, Schwarz H (2001) Musculoskeletal analyses of the forearm in young women with Turner syndrome: a study using peripheral quantitative computed tomography. J Clin Endocrinol Metab 86(12):5819–5823CrossRefPubMed
32.
Zuckerman-Levin N, Yaniv I, Schwartz T, Guttmann H, Ze Hochberg (2007) Normal DXA bone mineral density but frail cortical bone in Turner’s syndrome. Clin Endocrinol (Oxf) 67(1):60–64CrossRef
33.
Crofton PM, Evans N, Bath LE, Warner P, Whitehead TJ, Critchley HO, Kelnar CJ, Wallace WHB (2010) Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. Clin Endocrinol (Oxf) 73(6):707–714CrossRef
34.
Cavallo L, Gurrado R, Syndrome ISGfT (1999) Endogenous growth hormone secretion does not correlate with growth in patients with Turner’s syndrome. J Pediatr Endocrinol Metab 12(5):623–628CrossRefPubMed
35.
Pirazzoli P, Mazzanti L, Bergamaschi R, Perri A, Scarano E, Nanni S, Zucchini S, Gualandi S, Cicognani A, Cacciari E (1999) Reduced spontaneous growth hormone secretion in patients with Turner’s syndrome. Acta Paediatr 88(6):610–613CrossRefPubMed
36.
Bonjour J-P, Carrie A-L, Ferrari S, Clavien H, Slosman D, Theintz G, Rizzoli R (1997) Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J Clin Invest 99(6):1287CrossRefPubMedPubMedCentral
37.
Bonjour J-P, Chevalley T, Ammann P, Slosman D, Rizzoli R (2001) Gain in bone mineral mass in prepubertal girls 3–5 years after discontinuation of calcium supplementation: a follow-up study. Lancet 358(9289):1208–1212CrossRefPubMed
38.
Chevalley T, Rizzoli R, Hans D, Ferrari S, Bonjour J-P (2005) Interaction between calcium intake and menarcheal age on bone mass gain: an eight-year follow-up study from prepuberty to postmenarche. J Clin Endocrinol Metab 90(1):44–51CrossRefPubMed
39.
Slemenda CW, Peacock M, Hui S, Zhou L, Johnston CC (1997) Reduced rates of skeletal remodeling are associated with increased bone mineral density during the development of peak skeletal mass. J Bone Miner Res 12(4):676–682CrossRefPubMed
40.
Khatchadourian K, Huot C, Alos N, Van Vliet G, Deal C (2008) Impact of patient characteristics and clinical factors on the decision to initiate growth hormone treatment in Turner syndrome. Horm Res 70(5):300–308CrossRefPubMed
41.
Centers for Disease Control and Prevention (2000) CDC growth charts for the United States. National Center for Health Statistics
42.
Metadata
Title
Impact of Growth Hormone on Adult Bone Quality in Turner Syndrome: A HR-pQCT Study
Authors
Munier A. Nour
Lauren A. Burt
Rebecca J. Perry
David K. Stephure
David A. Hanley
Steven K. Boyd
Publication date
01-01-2016
Publisher
Springer US
Published in
Calcified Tissue International / Issue 1/2016
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-015-0064-8

Other articles of this Issue 1/2016

Calcified Tissue International 1/2016 Go to the issue

Original Research

Evaluation of a Modified Pamidronate Protocol for the Treatment of Osteogenesis Imperfecta

Original Research

Osteogenesis Imperfecta Type I Caused by COL1A1 Deletions

Original Research

Effect of Milk Powder Supplementation with Different Calcium Contents on Bone Mineral Density of Postmenopausal Women in Northern China: A Randomized Controlled Double-Blind Trial

Original Research

Ladder-Climbing Training Prevents Bone Loss and Microarchitecture Deterioration in Diet-Induced Obese Rats

Original Research

Advanced Age, High β-CTX Levels, and Impaired Renal Function are Independent Risk Factors for All-Cause One-Year Mortality in Hip Fracture Patients

Original Research

The Preventive Effect of Calcium Supplementation on Weak Bones Caused by the Interaction of Exercise and Food Restriction in Young Female Rats During the Period from Acquiring Bone Mass to Maintaining Bone Mass
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits